Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes
Sponsor: Allied Hospital Faisalabad
Summary
The goal of this randomized controlled trial is to compare two medicines added to metformin for blood sugar control in adults with type 2 diabetes whose HbA1c remains between 7.0% and 10.0% despite a stable dose of metformin. The main question it aims to answer is: Does adding sotagliflozin (a dual SGLT1/SGLT2 inhibitor) lower HbA1c more than adding empagliflozin (a selective SGLT2 inhibitor) after 24 weeks? Participants will continue their usual metformin dose and will be randomly assigned to take either sotagliflozin 200 mg or empagliflozin 10 mg once daily for 24 weeks. They will be reviewed at 4, 12 and 24 weeks for adherence, side effects and adverse events, and HbA1c will be measured at baseline and at 24 weeks.
Official title: Comparison of the Effect of Metformin-Sotagliflozin Versus Metformin-Empagliflozin Combination Therapy on Glycemic Control Measured by HbA1c in Patients With Type 2 Diabetes Mellitus
Key Details
Gender
All
Age Range
30 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2026-12-01
Completion Date
2028-01-31
Last Updated
2026-11-16
Healthy Volunteers
No
Conditions
Interventions
Sotagliflozin
200 mg tablet orally once daily for 24 weeks
Empagliflozin (oral)
10 mg tablet orally once daily for 24 weeks
Metformin
continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated)
Locations (1)
Allied Hospital, Faisalabad Medical University
Faisalabad, Punjab Province, Pakistan